Immix Biopharma (IMMX) discloses 39,643-share stock option grant to director

Rhea-AI Filing Summary

Immix Biopharma director Dr. Nancy T. Chang reported an equity award dated 11/21/2025. She received a stock option (right to buy common stock) for 39,643 shares at an exercise price of $4.33 per share, exercisable until 11/21/2035.

The option will vest in 36 equal monthly installments following the grant date, subject to her continued service and a stock option agreement. After the reported transaction, she beneficially owned 421,940 shares of common stock directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and may be deemed to beneficially own those securities while disclaiming ownership beyond her pecuniary interest.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider CHANG NANCY T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,643	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 39,643 shares (Direct); Common Stock — 421,940 shares (Direct); Common Stock — 496,940 shares (Indirect, Held by Robinhood II, LP)

Footnotes (1)

1. Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. Dr. Chang disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein. The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer and the terms of a Stock Option Agreement entered into to evidence the award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHANG NANCY T

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								421,940	D
Common Stock								496,940	I	Held by Robinhood II, LP(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.33	11/21/2025		A		39,643		(2)	11/21/2035	Common Stock	39,643	$0.00	39,643	D

Explanation of Responses:

1. Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. Dr. Chang disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.

2. The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer and the terms of a Stock Option Agreement entered into to evidence the award.

	/s/ Dr. Nancy T. Chang	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immix Biopharma (IMMX) report for Dr. Nancy T. Chang?

The company reported that Dr. Nancy T. Chang received a stock option (right to buy common stock) for 39,643 shares at an exercise price of $4.33 per share on 11/21/2025.

What are the key terms of Dr. Chang’s Immix Biopharma stock option?

The stock option covers 39,643 shares of common stock at $4.33 per share, is exercisable until 11/21/2035, and will vest in 36 equal monthly installments after the grant date, subject to continued service and a stock option agreement.

How many Immix Biopharma shares does Dr. Chang beneficially own after the transaction?

Following the reported transaction, Dr. Chang beneficially owned 421,940 shares of Immix Biopharma common stock directly and 496,940 shares indirectly through Robinhood II, LP.

What is Dr. Chang’s relationship to Robinhood II, LP in the Immix Biopharma (IMMX) filing?

Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the Immix Biopharma securities held by Robinhood II, LP, but she disclaims beneficial ownership except to the extent of her pecuniary interest.

How does the Immix Biopharma (IMMX) stock option for Dr. Chang vest over time?

The stock option will vest in thirty-six (36) equal monthly installments following the 11/21/2025 grant date, subject to Dr. Chang’s continued service with Immix Biopharma and the terms of the related stock option agreement.